Group 1 - The core point of the news is the strategic partnership between Link Health Biotechnology Group and Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug Bogu Tai® in six countries [1][2] - Bogu Tai® is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The target market for this partnership includes over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai® in these underserved markets [1] Group 2 - Since its launch in China in March 2024, Bogu Tai® has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The partnership is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2]

Group 1 - The core point of the news is the strategic partnership between Link Health Biotechnology Group and Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug, Bogu Tai, in six countries [1][2] - Bogu Tai is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The target market for this partnership includes over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai in these underserved markets [1] Group 2 - Since its launch in China in March 2024, Bogu Tai has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The collaboration is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2]

Group 1 - The core point of the news is the strategic partnership between Beijing Bokan Gene Technology Co., Ltd. and Sinovac Biotech Ltd. for the exclusive commercialization of the osteoporosis treatment drug Bogu Tai® in six countries, which presents significant market opportunities [1] - Bogu Tai® is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures, addressing unmet medical needs in the market [1] - The target market for this partnership includes over 10 million osteoporosis patients with a market size of nearly $1.5 billion, indicating a substantial opportunity for growth [1] Group 2 - Sinovac Biotech is a leading innovative multinational biopharmaceutical company with operations in multiple countries and regions, which has achieved market access and sales in dozens of global markets [2] - The board of Sinovac Biotech views this collaboration as a key milestone in its global expansion strategy, reinforcing its position in the osteoporosis treatment market and providing long-term value for shareholders [2] - Since its launch in China in March 2024, Bogu Tai® has seen significant success, with revenue growth of 248.9% year-on-year in the first half of 2025, indicating strong market demand and performance [1]

Core Viewpoint - 联康生物科技集团 has entered into a strategic cooperation agreement with 科兴制药 for the exclusive commercialization of its innovative osteoporosis treatment drug, 博固泰, in six countries [1] Group 1: Company Overview - 联康生物科技集团's subsidiary, 北京博康健基因科技有限公司, will collaborate with 科兴制药 to expand the market for 博固泰 in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico [1] - 博固泰 is recognized as China's first approved pre-filled teriparatide injection, designed to enhance patient comfort and adherence through a fine needle and precise delivery system [1] Group 2: Product Details - 博固泰 is a next-generation osteoporosis treatment that promotes bone formation and increases bone density, addressing significant unmet medical needs for postmenopausal women at high risk of fractures [1]

Group 1 - The core point of the news is that Link Health Biotechnology Group has signed a strategic cooperation agreement with Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug, Bogu Tai, in six countries [1] - Bogu Tai is a new generation osteoporosis treatment drug that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The cooperation area has over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai to enter these unmet market needs [1] Group 2 - Since its launch in China in March 2024, Bogu Tai has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The partnership is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2] - The competitive pricing strategy is expected to yield higher profit margins for Bogu Tai, with revenue realization anticipated by the end of 2026 [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 布 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 自願性公佈 科 興 製 藥（ 股 票 代 碼 ： 688136.SH ）是 一 家 領 先 的 創 新 型 跨 國 生 物 製 藥 企 業 ， 其 設 立 並 運 營 6 家 海 外 子 公 司和 辦 事 處 ， 已 通 過 歐盟 、 巴 西 、 菲 律 賓 、 印度 尼 西 亞 等 全球幾十個國家和地區的市場准入並實現銷售。 聯康生物科技集團通過戰略合作拓展博固泰®全球市場 香港，二零二五年九月十二日 — 聯康生物科技集團有限公司（「本公司」），連同其 附屬公司統稱（「本集團」）董事會（「董事會」）欣然宣佈，其全資子公司北京博康健基 因科技有限公司（「北京博康健」）與科興生 ...

Market Overview - The biopharmaceutical sector experienced a slight increase of 0.0% on September 12, with Aopumai leading the gains [1] - The Shanghai Composite Index closed at 3883.69, up by 0.22%, while the Shenzhen Component Index closed at 12996.38, up by 0.13% [1] Top Gainers in Biopharmaceutical Sector - Aopumai (688293) closed at 54.00, with a rise of 4.73% and a trading volume of 20,300 lots, totaling a transaction value of 103 million [1] - Kexing Pharmaceutical (688136) closed at 42.28, increasing by 3.45% with a trading volume of 47,400 lots, amounting to 197 million [1] - Sanofi (688336) closed at 57.07, up by 3.39% with a trading volume of 52,600 lots, totaling 294 million [1] - Tibet Pharmaceutical (600211) closed at 56.60, rising by 3.38% with a trading volume of 93,300 lots, totaling 510 million [1] - Wenqu Pharmaceutical (688488) closed at 16.00, increasing by 2.83% with a trading volume of 86,300 lots, amounting to 134 million [1] Top Decliners in Biopharmaceutical Sector - Rongchang Biopharmaceutical (688331) closed at 107.22, down by 2.68% with a trading volume of 56,400 lots, totaling 611 million [2] - Wanze Shares (000534) closed at 16.02, decreasing by 2.61% with a trading volume of 135,500 lots, amounting to 218 million [2] - Kangtai Biopharmaceutical (300601) closed at 18.63, down by 1.48% with a trading volume of 156,700 lots, totaling 292 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 310 million from institutional investors, while retail investors experienced a net inflow of 132 million [2] - Notable net inflows from retail investors were observed in Kanghua Biological (300841) with 94.86 million, and Xizang Pharmaceutical (600211) with 49.76 million [3] - Conversely, significant net outflows were noted in Rongchang Biopharmaceutical (688331) with 17.13 million and Aopumai (688293) with 18.19 million from retail investors [3]

Market Overview - The Shanghai Composite Index closed at 3870.60 points, slightly above the six-month moving average, with a change of -0.12% [1] - The total trading volume of A-shares reached 25,483.12 billion yuan [1] Stocks Breaking the Six-Month Line - A total of 50 A-shares have surpassed the six-month moving average today, with notable stocks including Shanghai Construction, Yihualu, and Runjian Shares, showing divergence rates of 9.89%, 9.08%, and 9.07% respectively [1] - Stocks with smaller divergence rates that just crossed the six-month line include Zhuhai Port, Zhongzhou Special Materials, and Nanjing Chemical Fiber [1] Top Performers - Shanghai Construction (600170) saw a price increase of 9.96% with a turnover rate of 6.20% and a divergence rate of 9.89% [1] - Yihualu (300212) increased by 10.90% with a turnover rate of 12.71% and a divergence rate of 9.08% [1] - Runjian Shares (002929) rose by 9.99% with a turnover rate of 10.76% and a divergence rate of 9.07% [1] Additional Notable Stocks - Other significant gainers include Huafu Times (600169) with a 10.08% increase and a divergence rate of 7.82%, and Shang (002042) with a 10.06% increase and a divergence rate of 7.70% [1] - The stock of Fule New Materials (605488) rose by 10.01% with a divergence rate of 6.93% [1] Stocks with Lower Divergence Rates - Stocks like Zhonghuan Hailu (301040) and Baitong Energy (001376) showed increases of 1.91% and 1.55% respectively, with divergence rates of 1.09% and 1.00% [2] - Longyuan Construction (600491) increased by 1.91% with a divergence rate of 0.97% [2]

Core Viewpoint - The stock price of Kexing Pharmaceutical has shown significant volatility, with a year-to-date increase of 91.68%, but a recent decline in the last five and twenty trading days [2] Group 1: Stock Performance - As of September 12, Kexing Pharmaceutical's stock price rose by 2.15% to 41.75 CNY per share, with a trading volume of 1.22 billion CNY and a market capitalization of 8.402 billion CNY [1] - The stock has experienced a decline of 1.23% over the last five trading days and 6.45% over the last twenty trading days, while it has increased by 2.45% over the last sixty days [2] Group 2: Financial Performance - For the first half of 2025, Kexing Pharmaceutical reported a revenue of 700 million CNY, a year-on-year decrease of 7.82%, while the net profit attributable to shareholders was 80.3445 million CNY, reflecting a year-on-year increase of 576.45% [2] - The company has distributed a total of 51.5446 million CNY in dividends since its A-share listing, with 15.7785 million CNY distributed in the last three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Kexing Pharmaceutical increased by 16.86% to 9,412, while the average circulating shares per person decreased by 14.43% to 21,211 shares [2] - The top shareholders include E Fund Medical Healthcare Industry Mixed A, which increased its holdings by 1.6955 million shares, and other funds that have also adjusted their positions [3]

资料显示，科兴生物制药股份有限公司位于山东省济南市章丘区埠村街道创业路2666号,广东省深圳市 南山区高新中一道与科技中一路交汇处创益科技大厦19楼，成立日期1997年8月22日，上市日期2020年 12月14日，公司主营业务涉及从事重组蛋白药物和微生态制剂的研发、生产、销售。主营业务收入构成 为：医药产品97.38%，其他2.62%。 科兴制药所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：肝炎治疗、动物疫 苗、多肽药、细胞治疗、创新药等。 9月9日，科兴制药盘中下跌2.02%，截至13:17，报41.69元/股，成交1.31亿元，换手率1.52%，总市值 83.90亿元。 资金流向方面，主力资金净流入1034.82万元，特大单买入356.43万元，占比2.73%，卖出478.36万元， 占比3.67%；大单买入4183.92万元，占比32.06%，卖出3027.17万元，占比23.19%。 科兴制药今年以来股价涨91.41%，近5个交易日跌3.41%，近20日跌7.68%，近60日跌5.23%。 今年以来科兴制药已经6次登上龙虎榜，最近一次登上龙虎榜为7月3日。 机构持仓方面，截止20 ...